{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High-Risk&page=36",
    "query": {
      "condition": "High-Risk",
      "page": 36
    },
    "page_size": 10
  },
  "pagination": {
    "page": 36,
    "page_size": 10,
    "total_count": 7258,
    "total_pages": 726,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High-Risk&page=37&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High-Risk&page=35&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-06T20:23:09.601Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06606743",
      "title": "Interval Training and Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Other Disorders of Autonomic Nervous System"
      ],
      "interventions": [
        {
          "name": "High-Intensity Interval Training",
          "type": "BEHAVIORAL"
        },
        {
          "name": "High-Velocity Circuit Resistance Training",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "30 Years to 90 Years"
      },
      "enrollment_count": 39,
      "start_date": "2024-09-20",
      "completion_date": "2025-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-08-15",
      "last_synced_at": "2026-11-06T20:23:09.601Z",
      "location_count": 2,
      "location_summary": "Coral Gables, Florida",
      "locations": [
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06606743"
    },
    {
      "nct_id": "NCT04541225",
      "title": "Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioma",
        "Glioma, Malignant",
        "Glioma, Mixed",
        "Glial Cell Tumors",
        "Breast Cancer",
        "Breast Carcinoma",
        "Cancer of Breast",
        "Cancer of the Breast",
        "Breast Tumor",
        "Malignant Tumor of Breast",
        "Advanced Breast Cancer",
        "Advanced Breast Carcinoma",
        "Metastatic Breast Cancer",
        "Metastatic Breast Carcinoma",
        "Prostate Cancer",
        "Prostatic Cancer",
        "Cancer of Prostate",
        "Cancer of the Prostate",
        "Prostate Neoplasm",
        "Castrate Resistant Prostate Cancer",
        "Castration-resistant Prostate Cancer",
        "Castration Resistant Prostatic Neoplasms",
        "Glioblastoma",
        "Recurrent Glioblastoma"
      ],
      "interventions": [
        {
          "name": "NUV-422",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nuvation Bio Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 74,
      "start_date": "2020-12-08",
      "completion_date": "2022-08-31",
      "has_results": false,
      "last_update_posted_date": "2023-07-14",
      "last_synced_at": "2026-11-06T20:23:09.601Z",
      "location_count": 12,
      "location_summary": "Tucson, Arizona • Miami, Florida • Boston, Massachusetts + 9 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Huntersville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04541225"
    },
    {
      "nct_id": "NCT06185023",
      "title": "Effects of High-intensity Exercise Training on Physical Fitness, Cognition, Language in Post-stroke Aphasia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Aphasia, Acquired",
        "Aphasia",
        "Aphasia, Fluent",
        "Aphasia Non Fluent"
      ],
      "interventions": [
        {
          "name": "Low-intensity physical exercise",
          "type": "BEHAVIORAL"
        },
        {
          "name": "High-intensity physical exercise",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of California, Berkeley",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 12,
      "start_date": "2023-12-11",
      "completion_date": "2026-01-15",
      "has_results": false,
      "last_update_posted_date": "2026-02-17",
      "last_synced_at": "2026-11-06T20:23:09.601Z",
      "location_count": 4,
      "location_summary": "Berkeley, California • Hayward, California • San Francisco, California",
      "locations": [
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Hayward",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06185023"
    },
    {
      "nct_id": "NCT07517068",
      "title": "The Role of Acetazolamide in Mitigating Inflammation and Innate Immune Activation at High Altitude",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Hypoxemia",
        "Acute Mountain Sickness (AMS)",
        "Inflammation",
        "Immune Response"
      ],
      "interventions": [
        {
          "name": "ACETAZOLAMIDE oral capsule",
          "type": "DRUG"
        },
        {
          "name": "Placebo Arm",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "University of California, Riverside",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 19,
      "start_date": "2025-09-17",
      "completion_date": "2026-12-15",
      "has_results": false,
      "last_update_posted_date": "2026-04-08",
      "last_synced_at": "2026-11-06T20:23:09.601Z",
      "location_count": 1,
      "location_summary": "Riverside, California",
      "locations": [
        {
          "city": "Riverside",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07517068"
    },
    {
      "nct_id": "NCT04196491",
      "title": "A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "bb2121",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2020-05-27",
      "completion_date": "2023-06-07",
      "has_results": false,
      "last_update_posted_date": "2023-08-23",
      "last_synced_at": "2026-11-06T20:23:09.601Z",
      "location_count": 22,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • San Francisco, California + 15 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04196491"
    },
    {
      "nct_id": "NCT00968071",
      "title": "Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Decitabine",
          "type": "DRUG"
        },
        {
          "name": "Gemtuzumab Ozogamicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 71,
      "start_date": "2008-02",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2013-03-08",
      "last_synced_at": "2026-11-06T20:23:09.601Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00968071"
    },
    {
      "nct_id": "NCT05739136",
      "title": "MYFEMBREE®: A Retrospective Cohort Study Using an Administrative Healthcare Database to Assess Pregnancy Outcomes in Women Treated With Relugolix Combination Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pregnancy Related",
        "Pregnancy Complications",
        "Pregnancy, High Risk"
      ],
      "interventions": [
        {
          "name": "Relugolix + Estradiol + Norethindrone Acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma Switzerland GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 530,
      "start_date": "2025-04-30",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2025-08-01",
      "last_synced_at": "2026-11-06T20:23:09.601Z",
      "location_count": 1,
      "location_summary": "Marlborough, Massachusetts",
      "locations": [
        {
          "city": "Marlborough",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05739136"
    },
    {
      "nct_id": "NCT01647711",
      "title": "A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "Dose escalation followed by treatment with MTD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2012-07",
      "completion_date": "2015-09",
      "has_results": true,
      "last_update_posted_date": "2017-01-31",
      "last_synced_at": "2026-11-06T20:23:09.601Z",
      "location_count": 2,
      "location_summary": "Aurora, Colorado • Boston, Massachusetts",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01647711"
    },
    {
      "nct_id": "NCT00000436",
      "title": "Improving Functional Recovery After Hip Fracture",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Unilateral Hip Fracture"
      ],
      "interventions": [
        {
          "name": "Self-efficacy and muscle strength training",
          "type": "BEHAVIORAL"
        },
        {
          "name": "High-intensity strength training",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "PROCEDURE"
      ],
      "sponsor": "National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "1993-07",
      "completion_date": "2000-06",
      "has_results": false,
      "last_update_posted_date": "2007-01-04",
      "last_synced_at": "2026-11-06T20:23:09.601Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000436"
    },
    {
      "nct_id": "NCT00303667",
      "title": "Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia"
      ],
      "interventions": [
        {
          "name": "aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "natural killer cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "allogeneic hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "total body irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Thymoglobulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclosporin A",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 50,
      "start_date": "2005-01",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2017-12-28",
      "last_synced_at": "2026-11-06T20:23:09.601Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00303667"
    }
  ]
}